Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday

Gilead Sciences (NASDAQ:GILD) is projected to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of $2.16 per share and revenue of $7.4151 billion for the quarter. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS.Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the business posted $2.01 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, analysts expect Gilead Sciences to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Stock Performance

GILD opened at $121.46 on Thursday. The business’s 50-day moving average price is $115.38 and its two-hundred day moving average price is $110.78. Gilead Sciences has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a market capitalization of $150.71 billion, a price-to-earnings ratio of 24.20, a P/E/G ratio of 0.85 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,500 shares of company stock worth $8,281,540. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Worldquant Millennium Advisors LLC bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $86,173,000. Sofinnova Investments Inc. boosted its holdings in shares of Gilead Sciences by 150.7% during the second quarter. Sofinnova Investments Inc. now owns 1,050,308 shares of the biopharmaceutical company’s stock worth $116,448,000 after acquiring an additional 631,408 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of Gilead Sciences by 47.7% during the second quarter. Quantinno Capital Management LP now owns 270,019 shares of the biopharmaceutical company’s stock worth $29,937,000 after acquiring an additional 87,191 shares during the period. Captrust Financial Advisors boosted its holdings in shares of Gilead Sciences by 2.8% during the second quarter. Captrust Financial Advisors now owns 1,878,626 shares of the biopharmaceutical company’s stock worth $208,283,000 after acquiring an additional 51,571 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Gilead Sciences by 1.4% during the second quarter. CANADA LIFE ASSURANCE Co now owns 2,227,558 shares of the biopharmaceutical company’s stock worth $247,158,000 after acquiring an additional 31,793 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. BMO Capital Markets lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday. The Goldman Sachs Group lifted their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday, October 17th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $121.14.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.